Do I Qualify for Mounjaro Weight Loss?

Last reviewed: July 11, 2026

Last updated: July 11, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Tirzepatide is a dual GLP-1 and GIP receptor agonist that has demonstrated average weight loss of 20% to 22% in clinical trials when combined with lifestyle changes. Unlike one-size-fits-all programs, PlexusDx uses a personalized screening process to match you with the right medication and dose based on your unique health profile and genetic predispositions.

Basic Health Requirements for Tirzepatide Eligibility

PlexusDx considers several baseline factors when evaluating tirzepatide candidates. You typically qualify if you have a BMI of 27 or higher with at least one weight-related health condition, or a BMI of 30 or higher regardless of comorbidities. Age requirements generally start at 18 years old, and you must be able to self-inject or have someone administer injections weekly.

Your medical history matters significantly in the qualification process. PlexusDx reviews prior medications, surgical procedures, allergies, and any history of pancreatitis or thyroid cancer—conditions that may contraindicate tirzepatide use. Kidney and liver function are also assessed through basic lab work to ensure safety before starting therapy.

How PlexusDx Personalizes Your Tirzepatide Assessment

Standard weight loss eligibility checklists miss the genetic reality: not everyone responds to tirzepatide the same way. PlexusDx offers the Precision Peptide Genetic Test, which analyzes 14 metabolic pathways and 49 peptides to reveal how your body processes GLP-1 and GIP signaling. Key genetic variants like GLP1R rs6923761, GIPR rs1800437, and FTO rs9939609 influence your likelihood of success with tirzepatide.

Beyond genetics, PlexusDx evaluates your metabolic phenotype through a comprehensive intake questionnaire covering appetite patterns, energy levels, food cravings, and previous medication responses. This multi-layered approach identifies whether tirzepatide injection, oral formulations, or alternative compounds like semaglutide will work best for your body and lifestyle.

Medical Conditions That Affect Tirzepatide Candidacy

Certain metabolic and endocrine conditions influence whether tirzepatide is appropriate. Type 2 diabetes patients often qualify and experience additional glucose control benefits alongside weight loss. However, if you have a personal or family history of medullary thyroid carcinoma, or if you are pregnant, planning pregnancy, or breastfeeding, tirzepatide is not recommended.

Cardiovascular health is also reviewed. Patients with stable hypertension or controlled heart disease can often use tirzepatide safely, but active heart disease, recent stroke, or uncontrolled arrhythmias require specialist clearance. PlexusDx coordinates with your primary care doctor or cardiologist to ensure tirzepatide fits your complete health picture.

Why PlexusDx Tirzepatide Eligibility Is About More Than BMI

The PlexusDx Precision Peptide Genetic Test analyzes GLP1R, GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to tirzepatide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Your compounded tirzepatide injection starts at $289/mo (or $249/mo on the 6-month plan) flat—no hidden flat per-compound pricing increases. Whether your therapy requires 2.5 mg weekly or 15 mg weekly, the monthly cost stays the same, ensuring you can commit to finding your optimal therapeutic dose without financial surprises. All medications come from licensed 503A compounding pharmacies, no insurance required, and HSA/FSA accounts are accepted across all 50 states.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $289/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What is the minimum BMI to qualify for PlexusDx tirzepatide?

PlexusDx typically recommends tirzepatide for patients with a BMI of 27 or higher with at least one weight-related comorbidity (such as hypertension, prediabetes, or sleep apnea), or a BMI of 30 or higher without additional conditions. However, individual qualification depends on your complete health assessment, not BMI alone.

Can I use tirzepatide if I have type 2 diabetes?

Yes, tirzepatide is particularly effective for patients with type 2 diabetes, offering dual benefits of weight loss and improved blood sugar control. PlexusDx coordinates with your endocrinologist or primary care provider to ensure tirzepatide dosing aligns with your diabetes management plan.

How much does PlexusDx tirzepatide cost monthly?

Compounded tirzepatide injection from PlexusDx starts at $289/mo (or $249/mo on the 6-month plan) flat across all dose levels. Your price remains the same whether you are taking a microdose or a full therapeutic dose—no flat per-compound pricing increases. HSA and FSA accounts are eligible, and insurance is not required.

What disqualifies someone from tirzepatide?

You should not use tirzepatide if you have a personal or family history of medullary thyroid carcinoma, are pregnant or breastfeeding, or have severe uncontrolled kidney or liver disease. Recent pancreatitis, active heart disease, or uncontrolled severe hypertension also require specialist evaluation before starting therapy.

How does the Precision Peptide Genetic Test improve my tirzepatide candidacy assessment?

PlexusDx's Precision Peptide Genetic Test ($99 add-on after your first month) analyzes variants in GLP1R, GIPR, FTO, and MC4R genes across 14 metabolic pathways to reveal your genetic predisposition to tirzepatide response. This 150+ insight report helps confirm whether tirzepatide is your ideal compound or if semaglutide or other options may work better.

Related Reading

• Mounjaro For Weight Loss 2
• Weight Loss Mounjaro
• Mounjaro Weight Loss By Week
• Weight Loss Injections Mounjaro

Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.